Physician profile
Michael Kam
NPI 1316040504
$14,308.85
in general payments reported to CMS, 2019-2025
39 companies · $3,477 in 2025
The $3,477 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $531 · 2021: $1,393 · 2022: $2,155 · 2023: $2,771 · 2024: $3,039 · 2025: $3,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,286.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,316.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,166.80 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,337.50 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $1,217.82 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $527.08 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $512.88 | 2019-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $474.01 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $439.02 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $388.07 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $365.92 | 2022-2025 | Tremfya |
| Ardelyx, INC. | $322.80 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $298.72 | 2023-2025 | Omvoh |
| Allergan, INC. | $277.00 | 2019-2020 | |
| Celgene Corporation | $271.79 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $265.67 | 2021-2025 | Sucraid, Sucraid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $254.59 | 2021-2023 | |
| Boston Scientific Corporation | $244.41 | 2020-2024 | Exalt Model D |
| Gilead Sciences, INC. | $220.30 | 2019-2023 | Vemlidy |
| Merck Sharp & Dohme LLC | $209.14 | 2019-2024 | Dificid |
| Pfizer INC. | $180.58 | 2023-2025 | |
| Redhill Biopharma INC. | $174.42 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Ipsen Biopharmaceuticals, INC | $133.00 | 2024-2025 | Iqirvo, Bylvay |
| E.R. Squibb & Sons, L.L.C. | $122.03 | 2021 | |
| Aimmune Therapeutics, INC. | $108.96 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $75.58 | 2023-2025 | Injectafer |
| Shire North American Group INC | $61.13 | 2019 | |
| Ferring Pharmaceuticals INC. | $48.93 | 2022-2023 | Rebyota |
| Organon LLC | $42.19 | 2021-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $40.66 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $36.49 | 2024-2025 | Givlaari |
| Concordia Pharmaceuticals INC. | $34.95 | 2019 | |
| Braintree Laboratories, INC. | $31.71 | 2019-2023 | Sutab, Suflave |
| Shield Therapeutics INC | $20.41 | 2024 | |
| Novo Nordisk INC | $17.42 | 2023 | Wegovy |
| Romark Laboratories, Lc | $16.99 | 2020 | |
| Lucid Diagnostics INC. | $15.65 | 2023 | |
| Capsovision, INC. | $13.12 | 2024 | Capsocam Plus |
| Ucb, INC. | $13.11 | 2019 | |
| Medtronic, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.